ArticleBlood advances2026
"Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBispecific T-cell engagers (BiTEs) provide high rates of responses in patients with relapsed and refractory B-cell lymphomas and multiple myeloma otherwise resistant to other therapies, but the duration of response to these treatments is limited in time. Allogeneic stem cell transplantation is a potentially curative approach for those disorders, although its indication is limited to patients who achieve remission. With no established strategies to improve the "graft-versus-tumor effect" available, relapses still account for most posttransplant failures. Here, we report, to our knowledge, the first case in literature of a successful treatment with glofitamab, a CD20X2/CD3 BiTE, in a posttransplant relapse of mantle cell lymphoma with central nervous disease involvement. We propose the combination of BiTEs and allogeneic transplant as an integrated and sequential immunologic approach to be tested in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.